A Phase 1/2 interventional study of EPI-321 in Facioscapulohumeral Muscular Dystrophy, sponsored by Epicrispr Biotechnologies, Inc.. Active, not recruiting at 7 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Epicrispr Biotechnologies, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.
Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 2 of the 12 other live ones, and was the 28th registered.
79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.
Browse Muscular Dystrophy, Facioscapulohumeral studies →8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:
Scholar Rock, Inc. · Sites in United States
Ages 18–60
Restem, LLC. · Sites in United States
Ages 15+
Jeffrey Statland · Sites in United States
Ages 18–75
Avidity Biosciences, Inc. · Sites in United States, Canada, Denmark and 7 more countries
Ages 16–70
University of Kansas Medical Center · Sites in United States, Australia
Ages 5–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 15 · Phase 3 2
First in 2000; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 48 across 49 interventional studies indexed under Muscular Dystrophy, Facioscapulohumeral.
Median enrollment 51 across the 21 interventional studies, 94 across the 11 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 32 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Epicrispr Biotechnologies, Inc. as lead sponsor.
Epicrispr Biotechnologies, Inc. has 1 study filed under Muscular Dystrophy, Facioscapulohumeral — fewer than ten, so there is no comparison to draw.
3 of the studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06847282University of Kansas Medical CenterMotor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) | 2027-05 |
| NCT05019625Massachusetts General HospitalBiomarker Development for Muscular Dystrophies | 2027-06 |
| NCT06907875Epicrispr Biotechnologies, Inc.A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | 2027-07-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are:
How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working?
Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321.
EPI-321 is an investigational drug product comprising a recombinant adeno-associated viral vector, serotype rh74 (AAVrh74), for the delivery of genetic material encoding an epigenetic editor designed to address the root case of FSHD. AAVrh74 has been shown to transduce human skeletal muscle efficiently in the clinical experience. EPI-321's transgene product, a non-cutting, nuclease-dead mini, clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein (dCasONYX) with fuse epigenetic modulators, is designed to selectively bind the D4Z4 repeat region via the accompanying guide RNA, methylate CpG groups within the region near the DUX4 gene on chromosome 4q35, and thus repress the expression of toxic DUX4 protein, ameliorating the downstream pathology that drives FSHD. As it is under a muscle-specific promoter, the dCasONYX-fused protein is expected to be preferentially and actively expressed in muscle tissue following a single intravenous (IV) dose.
EPI-321-02 clinical trial is an open label dose ascending study of EPI-321 for safety and tolerability to determine the best dose for a future trial of drug activity. Two dose levels will be evaluated. In addition, this study will collect secondary outcome data on muscle function, imaging characteristics, and other markers of disease activity at the baseline and throughout the study to assess their utility as measures of drug activity in a future clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single IV infusion of a target dose of 2x10\^13 vg/kg
Biological: EPI-321
Single IV infusion of a target dose of 4x10\^13 vg/kg
Biological: EPI-321
EPI-321 IV Infusion
Frequency of AEs and EPI-321 Related Adverse Reactions and Serious Adverse Reactions
All AEs, regardless of assessed relatedness to EPI-321, will be collected from the time of informed consent signature until the end of study participation. The Investigator is responsible for assessing the severity of an AE according to the NCI-CTCAE version 5.0.
Time frame: Baseline to up to 5 years.
Vector Copy Number
Change in vector copy number (as measured by vg/dg) within skeletal muscle biopsies.
Time frame: Baseline, 3 and 12 months
EPI-321 Cargo Transcriptional Activity
Change in EPI-321 cargo transcriptional activity within skeletal muscle biopsies.
Time frame: Baseline, 3 and 12 months
DUX4 Expression
Change in the expression of DUX4 and downstream markers (DUX4 Composite Score) within skeletal muscle biopsies.
Time frame: Baseline, 3 and 12 months
Methylation Status
Change from baseline in the methylation status of the 4q35 D4Z4 region within skeletal muscle biopsies at 3 and 12 months.
Time frame: Baseline, 3 and 12 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Facioscapulohumeral →